国际肿瘤学杂志

国际肿瘤学杂志››2012,Vol. 39››Issue (1): 50-53.

• 综述 •上一篇下一篇

进展期胃癌分子靶向治疗

王润洁, 石晓燕, 黄薇, 刘超英

  1. 214023无锡市人民医院肿瘤科
  • 出版日期:2012-01-08发布日期:2013-11-11
  • 通讯作者:刘超英，E-mail: chyliu666@163.com E-mail:chyliu666@163.com

Molecular targetedtherapy ofadvanced gastric cancer

WANG Run-Jie, SHI Xiao-Yan, HUANG Wei, LIU Chao-Ying

  1. Department of Oncology, Wuxi People’s Hospital, Wuxi 214023, China

  • Online:2012-01-08Published:2013-11-11
  • Contact:Corresponding author: LIU Chao-ying, E-mail: chyliu666@163.com E-mail:chyliu666@163.com

PDF

1891

被引次数

1

摘要：进展期胃癌化疗效果不佳。分子靶向治疗是近年来进展期胃癌综合治疗的新手段。目前这些策略主要包括针对表皮生长因子受体(EGFR)通道的靶向治疗、针对血管内皮生长因子通道的靶向治疗、口服小分子靶向药物等。近期有关HER2、EGFR、VEGF、mTOR信号通路的靶向药物曲妥珠单抗、西妥昔单抗、贝伐单抗、阿帕替尼、索拉非尼、舒尼替尼、拉帕替尼、RAD001（everolimus）等综合治疗进展期胃癌的报道结果令人鼓舞。

关键词:胃肿瘤,分子靶向治疗

Abstract:Efficacy of chemotherapy for advanced gastric cancer was unsatisfactory. Molecular targeted therapies have emerged as a novel approach to the treatment of advanced gastric cancer in recent years. These therapeutic strategies include targeting EGFR signal transduction pathway, anti-angiogenesis therapy, multi-target molecular targeted drugs. Targeted drugs such as trastuzumab, cetuximab, bevacizumab, apatinib, sorafenib sunitinib, lapatinib and everolimus which are targeting HER2, EGFR, VEGF and mTOR pathway, are applied in thecomprehensivetreatment of advanced gastric cancer, and theirtherapeuticeffects are encouraging.